NASDAQ:SCYX SCYNEXIS (SCYX) Stock Price, News & Analysis $1.51 -0.03 (-1.95%) (As of 10/17/2024 ET) Add Compare Share Share Stock Analysis Stock AnalysisAnalyst ForecastsChartCompetitorsEarningsFinancialsHeadlinesInsider TradesOptions ChainOwnershipSEC FilingsShort InterestTrends About SCYNEXIS Stock (NASDAQ:SCYX) 30 days 90 days 365 days Advanced Chart View Price History Chart DataSkip Price History Chart Get SCYNEXIS alerts:Sign Up Key Stats Today's Range$1.50▼$1.5450-Day Range$1.27▼$1.7852-Week Range$1.26▼$3.07Volume103,058 shsAverage Volume100,381 shsMarket Capitalization$57.17 millionP/E RatioN/ADividend YieldN/APrice TargetN/AConsensus RatingBuy Company OverviewSCYNEXIS, Inc., a biotechnology company, develops medicines to overcome and prevent difficult-to-treat and drug-resistant infections in the United States. It offers BREXAFEMME for the treatment of patients with vulvovaginal candidiasis (VVC) and recurrent VVC. The company's lead product candidate is Ibrexafungerp, an intravenous drug for the treatment of invasive candidiasis and/or candidemia, refractory invasive fungal infections, invasive aspergillosis, VVC, and recurrent VVC. It also develops SCY-247 to treat systemic fungal diseases. The company has licensing and collaboration agreements with GlaxoSmithKline Intellectual Property (No. 3) Limited, Merck Sharp & Dohme Corp., Hansoh (Shanghai) Health Technology Co., Ltd., Jiangsu Hansoh Pharmaceutical Group Company Limited, and R-Pharm, CJSC for the development, manufacture, and commercialization of ibrexafungerp. SCYNEXIS, Inc. was formerly known as SCYNEXIS Chemistry & Automation, Inc. and changed its name to SCYNEXIS, Inc. in June 2002. The company was incorporated in 1999 and is headquartered in Jersey City, New Jersey.Read More… Don’t Buy Another Stock Until Reading This… (Ad)Buying stocks in today's market is a gamble… Unless you're using the right proven strategy! During my upcoming FREE intro to investing online event, my team will be revealing the strategies I've developed over the past 37 years on Wall Street…Click here to claim your seat at my Intro to Investing class now! SCYNEXIS Stock Analysis - MarketRank™See Top Rated MarketRank™ Stocks20th Percentile Overall ScoreSCYX MarketRank™: SCYNEXIS scored higher than 20% of companies evaluated by MarketBeat, and ranked 909th out of 1,013 stocks in the medical sector. Scores are calculated by averaging available category scores, with extra weight given to analysis and valuation. Analyst's OpinionN/AAnalyst RatingN/A Consensus RatingThere is not enough analysis data for SCYNEXIS.Read more about SCYNEXIS's stock forecast and price target. Earnings and Valuation1.3 / 5Proj. Earnings GrowthGrowing Earnings GrowthEarnings for SCYNEXIS are expected to grow in the coming year, from ($0.68) to $0.07 per share.Price to Earnings Ratio vs. the MarketThe P/E ratio of SCYNEXIS is -2.10, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.Price to Earnings Ratio vs. SectorThe P/E ratio of SCYNEXIS is -2.10, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.Price to Book Value per Share RatioSCYNEXIS has a P/B Ratio of 0.77. P/B Ratios below 1 indicate that a company could be undervalued with respect to its assets and liabilities.Read more about SCYNEXIS's valuation and earnings. Short Interest2.0 / 5Short Interest LevelBearish Percentage of Shares Shorted2.67% of the outstanding shares of SCYNEXIS have been sold short.Short Interest Ratio / Days to CoverSCYNEXIS has a short interest ratio ("days to cover") of 7.5.Change versus previous monthShort interest in SCYNEXIS has recently increased by 2.45%, indicating that investor sentiment is decreasing. Dividend0.0 / 5Dividend StrengthN/A Dividend YieldSCYNEXIS does not currently pay a dividend.Dividend GrowthSCYNEXIS does not have a long track record of dividend growth. Sustainability and ESGN/AEnvironmental ScoreN/A Percentage of Shares Shorted2.67% of the outstanding shares of SCYNEXIS have been sold short.Short Interest Ratio / Days to CoverSCYNEXIS has a short interest ratio ("days to cover") of 7.5.Change versus previous monthShort interest in SCYNEXIS has recently increased by 2.45%, indicating that investor sentiment is decreasing. News and Social Media1.5 / 5News SentimentN/A News SentimentSCYNEXIS has a news sentiment score of 0.67. This score is calculated as an average of sentiment of articles about the company over the last seven days and ranges from 2 (good news) to -2 (bad news). This news sentiment score is similar to the average news sentiment of Medical companies.News Coverage This WeekMarketBeat has tracked 1 news article for SCYNEXIS this week, compared to 1 article on an average week. Company Ownership2.5 / 5Insider TradingAcquiring Shares Insider Buying vs. Insider SellingIn the past three months, SCYNEXIS insiders have bought more of their company's stock than they have sold. Specifically, they have bought $27,400.00 in company stock and sold $0.00 in company stock.Percentage Held by InsidersOnly 2.85% of the stock of SCYNEXIS is held by insiders.Percentage Held by Institutions54.37% of the stock of SCYNEXIS is held by institutions. High institutional ownership can be a signal of strong market trust in this company.Read more about SCYNEXIS's insider trading history. Receive SCYX Stock News and Ratings via Email Sign-up to receive the latest news and ratings for SCYNEXIS and its competitors with MarketBeat's FREE daily newsletter. Email Address SCYX Stock News HeadlinesSCYNEXIS to Participate in the 2024 Maxim Healthcare Virtual SummitOctober 10, 2024 | globenewswire.comFederated Hermes, Inc. Expands Stake in SCYNEXIS IncOctober 7, 2024 | finance.yahoo.comCrypto’s next big bull run?Juan Villaverde may be America’s top crypto expert. And he says something big is coming for crypto – on November 5. Just a day after the American election, Juan believes crypto could start a massive run up …October 18, 2024 | Weiss Ratings (Ad)SCYNEXIS (NASDAQ:SCYX) Stock Quotes, Forecast and News SummaryOctober 4, 2024 | benzinga.comSCYNEXIS to Present Preclinical Data on Second Generation Fungerp SCY-247 at IDWeek 2024October 3, 2024 | globenewswire.comSCYNEXIS to Participate in H. C. Wainwright 26th Annual Global Investment ConferenceAugust 27, 2024 | globenewswire.comBuy Rating Affirmed for SCYNEXIS Amid Antifungal Progress and Market PotentialAugust 13, 2024 | markets.businessinsider.comSCYNEXIS, Inc. (SCYX) stock historical prices & data – Yahoo FinanceAugust 9, 2024 | au.finance.yahoo.comSee More Headlines SCYX Stock Analysis - Frequently Asked Questions How have SCYX shares performed this year? SCYNEXIS's stock was trading at $2.23 at the beginning of 2024. Since then, SCYX stock has decreased by 32.3% and is now trading at $1.51. View the best growth stocks for 2024 here. How were SCYNEXIS's earnings last quarter? SCYNEXIS, Inc. (NASDAQ:SCYX) released its quarterly earnings results on Thursday, August, 8th. The company reported ($0.30) earnings per share for the quarter, missing the consensus estimate of ($0.19) by $0.11. The firm earned $0.74 million during the quarter. SCYNEXIS had a negative net margin of 366.09% and a negative trailing twelve-month return on equity of 57.41%. When did SCYNEXIS's stock split? SCYNEXIS's stock reverse split on the morning of Friday, July 17th 2020. The 1-10 reverse split was announced on Thursday, July 16th 2020. The number of shares owned by shareholders was adjusted after the market closes on Thursday, July 16th 2020. An investor that had 100 shares of stock prior to the reverse split would have 10 shares after the split. How do I buy shares of SCYNEXIS? Shares of SCYX stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Charles Schwab, E*TRADE, Fidelity, and Vanguard Brokerage Services. Compare Top Brokerages Here. What other stocks do shareholders of SCYNEXIS own? Based on aggregate information from My MarketBeat watchlists, some other companies that SCYNEXIS investors own include Zomedica (ZOM), Jumia Technologies (JMIA), NIO (NIO), Nano Dimension (NNDM), Sorrento Therapeutics (SRNE), Meta Platforms (META) and NVIDIA (NVDA). Company Calendar Last Earnings8/08/2024Today10/17/2024Next Earnings (Estimated)11/11/2024Fiscal Year End12/31/2024Get Stock AlertsIndustry, Sector and Symbol Stock ExchangeNASDAQ SectorMedical Industry Pharmaceutical preparations Sub-IndustryPharmaceutical Products Current SymbolNASDAQ:SCYX CUSIPN/A CIK1178253 Webwww.scynexis.com Phone(201) 884-5485Fax201-884-5490Employees60Year FoundedN/AProfitability EPS (Most Recent Fiscal Year)$2.04 Trailing P/E RatioN/A Forward P/E RatioN/A P/E GrowthN/ANet Income$67.04 million Net Margins-366.09% Pretax Margin-359.17% Return on Equity-57.41% Return on Assets-34.18% Debt Debt-to-Equity RatioN/A Current Ratio3.75 Quick Ratio3.75 Sales & Book Value Annual Sales$9.67 million Price / Sales5.90 Cash Flow$1.89 per share Price / Cash Flow0.80 Book Value$1.96 per share Price / Book0.77Miscellaneous Outstanding Shares37,780,000Free Float36,777,000Market Cap$57.05 million OptionableOptionable Beta1.50 The 10 Best AI Stocks to Own in 2024Wondering where to start (or end) with AI stocks? These 10 simple stocks can help investors build long-term wealth as artificial intelligence continues to grow into the future.Get This Free Report This page (NASDAQ:SCYX) was last updated on 10/18/2024 by MarketBeat.com Staff From Our PartnersDeFi Coin on Verge of Breakout!Grayscale Investments just announced a new fund offering access to a HOT new DeFi coin… And thanks to this ...Crypto 101 Media | SponsoredDon’t Buy Another Stock Until Reading This…Buying stocks in today's market is a gamble… Unless you're using the right proven strategy! During my up...Unstoppable Prosperity | SponsoredTim Sykes’ Urgent Trade Alert: “Make this move now”WARNING: 80 Wall Street banks are gearing up for MASSIVE D.C. shock This $2 trillion D.C. shock is NOT abou...Timothy Sykes | Sponsored320 hedge funds just sold this stock320 hedge funds just sold this stock A strange force has seized control of Wall Street. Hedge funds are alr...Chaikin Analytics | SponsoredCrypto’s next big bull run?Juan Villaverde may be America’s top crypto expert. And he says something big is coming for crypto – on Nov...Weiss Ratings | SponsoredWar on Elon Escalates… Elon Musk, the guy slated to become the world’s first trillionaire by 2027, has publicly called for the adopti...Porter & Company | SponsoredAdd $2T of Potential Magic to Your PortfolioRevolutionizing a whole $2T entertainment and licensing industry might sound like the stuff of fairytales. But...Elf Labs | SponsoredEquation for Profits: Volatility = OpportunityFREE Intro to Options Class Online Tonight Prosper Trading Academy | Sponsored Adding Choose a watchlist: Watchlist Adding You have already added five stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding SCYNEXIS, Inc. Please log in to your account or sign up in order to add this asset to your watchlist. Share SCYNEXIS With A Colleague Link copied to clipboard. Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.